Winklevoss Capital Sells its Zcash Mining Platforms to a Company It Backs and Acquires Shares of That Company

cryptonews.ruPublicado a 2026-08-20Actualizado a 2026-08-20

Resumen

Winklevoss Capital, through its Winklevoss Treasury Investments, has acquired a warrant for approximately 43.3 million shares of Cypherpunk Technologies Inc. (NASDAQ: CYPH) as part of a deal where Cypherpunk purchased a new Zcash mining venture. The transaction, valued at $33.33 million, dilutes existing shareholders and grants the Winklevoss brothers a significant stake in Zcash investments. Cypherpunk Mining, operating Z15 Pro machines with an estimated 18% of the Zcash network's Equihash hashrate, is positioned as the world's largest dedicated Zcash mining fleet, hosted at debt-free, low-cost U.S. facilities. The company aims to increase its ZEC holdings from the current 1.92% of the circulating supply to 5%, using mined coins to fund growth and new privacy technologies. Cameron Winklevoss framed the move as a play to bring Zcash mining dominance to the U.S., contrasting it with the historically foreign-concentrated mining landscape. Cypherpunk, formerly the biotech firm Leap Therapeutics, rebranded after a Winklevoss-led investment round. The announcement follows a period of volatility for Zcash, which faced a significant security flaw in early 2026, causing sharp declines in both ZEC and CYPH share prices before patches were deployed.

Winklevoss Capital received a warrant to acquire approximately 43.3 million company shares as part of Cypherpunk Technologies' purchase of a new Zcash mining enterprise.

This structure dilutes existing shareholders and gives the Gemini founders a larger stake in Zcash investments. Cypherpunk shares trade on Nasdaq under the ticker CYPH.

43,290,042 New Shares Lead to Dilution for Every CYPH Holder

Cypherpunk paid $33.33 million by issuing a pre-paid warrant to Winklevoss Treasury Investments for 43,290,042 common shares exercisable at $0.001 per share. This implies an estimated share price of $0.77 per share.

CYPH shares rose 15.85% on the August 18 session with trading volume roughly 4.2 times the daily average. A similar jump of 15.4% occurred following the May earnings report release.

The Cypherpunk Mining project is launched and operating on Z15 Pro machines. They generate an Equihash hash rate of ~4.2 GSol/s, which the company estimates accounts for about 18% of the total Zcash network.

The fleet is distributed across facilities in the U.S., and Cypherpunk calls it the world's largest Zcash operation. This is a potential market worth over $250 million annually at current $ZEC prices, compared to roughly 43,800 $ZEC in monthly network mining rewards.

The company already holds 323,394.38 $ZEC, about 1.92% of the total circulating cryptocurrency, and expresses a desire to acquire an additional 5%. Chief Investment Officer Will McEvoy stated that the mined coins give the company "financial and operational flexibility to fund future growth, acquire additional $ZEC, and invest in new privacy-enabling technologies."

The company invited Kevin Zhang, a long-time mining operator, to lead the mining operations.

Cameron Winklevoss Describes the Deal as a Play on the U.S. Market

"Zcash was concentrated in the hands of a small number of miners, pools, and ASIC manufacturers, almost all of which were outside the United States," Winklevoss wrote on X after the announcement.

He added that Cypherpunk's fleet is "hosted at facilities in the United States, is fully owned, debt-free, and has low energy costs." He and his brother Tyler presented the launch as a rare opportunity for public market investors to gain exposure to Zcash mining.

The company was originally named Leap Therapeutics, a biotech firm that rebranded as Cypherpunk Technologies in November 2025 following a $58.88 million private placement led by Winklevoss Capital, as Cryptopolitan reported. At that time, its treasury held approximately 203,775 $ZEC purchased at an average price of $245 per coin.

Earlier in 2026, Zcash faced a security issue when Shielded Labs researcher Taylor Hornby discovered a bug in the zero-knowledge scheme of the Orchard pool used by Zcash.

Theoretically, this could have allowed an attacker to create counterfeit $ZEC without detection. At the time, $ZEC prices fell by more than 50%, and Cypherpunk shares plunged by about 40%. Developers released an emergency patch in early June, followed by the Ironwood update in July.

Criptos en tendencia

Preguntas relacionadas

QWhat did Winklevoss Capital receive as part of the deal with Cypherpunk Technologies regarding the new Zcash mining venture?

AWinklevoss Capital received a warrant to purchase approximately 43.3 million shares of the company.

QWhat is the expected impact of the issuance of 43,290,042 new shares for Cypherpunk (CYPH)?

AThe issuance of the new shares is expected to dilute the stake of each existing CYPH shareholder.

QHow much of the total Zcash network hash rate does Cypherpunk Mining's fleet of Z15 Pro machines estimate to contribute?

ACypherpunk Mining's fleet estimates to contribute about 18% of the total Zcash network's hash rate.

QAccording to Cameron Winklevoss, what makes the Cypherpunk deal a unique opportunity for public market investors?

AHe described it as a rare opportunity for public market investors to gain access to Zcash mining, as the Cypherpunk fleet is US-located, fully owned, debt-free, and has low power costs.

QWhat security issue affected Zcash earlier in 2026, and what was its impact on CYPH stock?

AA bug was found in the zero-knowledge scheme of Zcash's Orchard pool, which theoretically could allow counterfeit ZEC creation. This caused ZEC's price to drop over 50% and CYPH stock to fall roughly 40%.

Lecturas Relacionadas

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbitHace 27 min(s)

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbitHace 27 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbitHace 28 min(s)

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbitHace 28 min(s)

Trading

Spot

Artículos destacados

Cómo comprar COMP

¡Bienvenido a HTX.com! Hemos hecho que comprar Compound (COMP) sea simple y conveniente. Sigue nuestra guía paso a paso para iniciar tu viaje de criptos.Paso 1: crea tu cuenta HTXUtiliza tu correo electrónico o número de teléfono para registrarte y obtener una cuenta gratuita en HTX. Experimenta un proceso de registro sin complicaciones y desbloquea todas las funciones.Obtener mi cuentaPaso 2: ve a Comprar cripto y elige tu método de pagoTarjeta de crédito/débito: usa tu Visa o Mastercard para comprar Compound (COMP) al instante.Saldo: utiliza fondos del saldo de tu cuenta HTX para tradear sin problemas.Terceros: hemos agregado métodos de pago populares como Google Pay y Apple Pay para mejorar la comodidad.P2P: tradear directamente con otros usuarios en HTX.Over-the-Counter (OTC): ofrecemos servicios personalizados y tipos de cambio competitivos para los traders.Paso 3: guarda tu Compound (COMP)Después de comprar tu Compound (COMP), guárdalo en tu cuenta HTX. Alternativamente, puedes enviarlo a otro lugar mediante transferencia blockchain o utilizarlo para tradear otras criptomonedas.Paso 4: tradear Compound (COMP)Tradear fácilmente con Compound (COMP) en HTX's mercado spot. Simplemente accede a tu cuenta, selecciona tu par de trading, ejecuta tus trades y monitorea en tiempo real. Ofrecemos una experiencia fácil de usar tanto para principiantes como para traders experimentados.

383 Vistas totalesPublicado en 2024.12.13Actualizado en 2026.06.02

Cómo comprar COMP

Discusiones

Bienvenido a la comunidad de HTX. Aquí puedes mantenerte informado sobre los últimos desarrollos de la plataforma y acceder a análisis profesionales del mercado. A continuación se presentan las opiniones de los usuarios sobre el precio de COMP (COMP).

活动图片